RT Journal Article
SR Electronic
T1 Sophisticated Prediction of Carotid-Plaque Vulnerability by Nanocluster Sensitized High-resolution Vessel-Wall-Imaging Profile in Rabbit Atherosclerotic Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.09.23287077
DO 10.1101/2023.03.09.23287077
A1 Gong, Yan
A1 Wu, Menglin
A1 Fu, Dingwei
A1 Guo, Yu
A1 Lu, Xiudi
A1 Zou, Ying
A1 Zhang, Xiang
A1 Zhu, Jinxia
A1 Zhang, Xianchang
A1 Li, Xue
A1 Xia, Shuang
YR 2023
UL http://medrxiv.org/content/early/2023/03/13/2023.03.09.23287077.abstract
AB OBJECTIVE To innovatively developed a macrophage-target nanoparticle based contrast-enhanced high-resolution magnetic resonance vessel wall imaging (HR-VWI) strategy to characterize the plaques’ vulnerable features on rabbits.BACKGROUND Lacking of sensitive and specific image-marker of HR-VWI leads this technique depending upon the plaque morphological characteristics. Nanoparticle-based contrast agents modified with targeting ligands allow amplifying MR signals of the interested components. The key to successful translation is the requirement that conducting studies in larger animals to provide reasonable diagnostic readouts.METHODS The HR-VWI enhanced with macrophage-targeted PP1-Au@GSH@Gd (GdMG) nanoclusters (NCs) and the conventional Gadovist were utilized for the plaque vulnerability evaluation by a systematic histogram analysis in atherosclerosis (AS) rabbit model.RESULTS Due to the compelling targeting capacity of GdMG NCs to foamy macrophages, the contrast-to-noise ratio (CNR) from pre-injection baseline dramatically raised from 6.50 to 36.91 (p < 0.001), with an increment of 1.39-fold higher than that of the Gadovist approach. Spearman’ s correlation test confirmed that the coefficient of variation (CV) derived from the histogram analysis based on GdMG NCs HR-VWI was indeed positively linearly correlated with pathology vulnerability index (VIP) significantly (p < 0.05) with adjusted R2 = 0.775. Finally, mathematic formulas with histogram-derived parameters as variables were fitted to quantitatively calculate the histogram vulnerability index (VIH) with the strength of the adjusted R2 = 0.952 (p < 0.001), and Area under the curve (AUC) of 0.875 (p < 0.001) to realize the in vivo and quantitative calculation of the plaque vulnerability.CONCLUSION Profiting from the splendid inflammation targeted capacity and excellent MRI performance of GdMG NCs, as well as the highly quantitative characteristics of histogram analysis, we disclosed that our established imaging protocol was able to identify the plaques’ vulnerability index that were comparable to pathological examinations in both retrospective and prospective experiments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Natural Science Foundation of China (82171916, 81871342), the Natural Scientific Foundation of Tianjin (21CYBJC01580), Tianjin Health Science and technology project (Specific projects of key disciplines) (TJWJ2022XK019), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-041A).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All protocols in this work were conducted with approval from the Institutional Animal Care and Use Committee of Nankai University (No. 2021-SYDWLL-000425). The experimental procedures were strictly conducted on the National Institutes of Health guidelines to make every effort to minimize rabbits' suffering and discomfort.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author,Shuang Xia, upon reasonable request.ASList AtherosclerosisGdMG NCsGd-modified macrophage-target gold nanoclustersHR-VWIhigh-resolution vessel wall imagingPPIa novel 16-mer peptide targeted scavenger receptorAI SR-Ascavenger receptors ATOF-MRAtime-of-flight magnetic resonance angiographyCVcoefficient of variation